Prospective assessment of glycopeptides prescriptions in a general hospital;Évaluation prospective de la prescription des glycopeptides dans un hôpital général

Medecine et Maladies Infectieuses

Volumn 35, Issue 7-8, 2005, Pages 411-416

  Levent, T ^a   Lambiotte, F ^a   Vasseur, M ^a   De Zorzi, S ^a   Gosteau, L ^a   Paradis, P ^a  

^a Centre Hospitalier de Sambre Avesnois   (France)

Author keywords

Antibioprophylaxis; Glycopeptides; Medical audit

Indexed keywords

BETA LACTAM ANTIBIOTIC; GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DENSITY; DRUG DOSE REGIMEN; GENERAL HOSPITAL; HOSPITAL ADMISSION; INCIDENCE; LABORATORY TEST; LENGTH OF STAY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; STANDARDIZATION; SURGICAL INFECTION; BACTERIAL INFECTION; BLOOD; DRUG RESISTANCE; DRUG UTILIZATION; FRANCE; HUMAN; MICROBIOLOGICAL EXAMINATION; PREMEDICATION; PREOPERATIVE CARE; PROSPECTIVE STUDY; STATISTICS; UTILIZATION REVIEW;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; DRUG RESISTANCE; DRUG UTILIZATION; FRANCE; GUIDELINE ADHERENCE; HOSPITALS, GENERAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES; PREMEDICATION; PREOPERATIVE CARE; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; TEICOPLANIN; VANCOMYCIN;

EID: 24944542832     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medmal.2005.06.005     Document Type: Article

References (23)

1. Le dictionnaire 2004 Vidal
2. E. Pilly 2004. 19°édition.
3. Recommandations pour la pratique de l'antibioprophylaxie en chirurgie. Actualisation 1999. Sociét́ Francaise d'Anesthésie et de Réanimation.
4. Hospital infection control practices advisory committee Recommendations for preventing the spread of vancomycin resistance Infect. Control Hosp. Epidemiol. 16 1995 105 113
5. R. Leclerq ́pid́miologie et facteurs de risques d'acquisition de staphylocoques ŕsistants Med. Mal. Infect. 34 2004 S179 S183
6. M. Eveillard, F.X. Lescure, and J.L. Schmit Portage, acquisition et transmission de Staphylococcus aureus ŕsistant ̀ la ḿticilline en milieu communautaire. Conśquences en terme de politique de pŕvention et d'antibioth́rapie Med. Mal. Infect. 32 2002 717 724
7. C. Brun-Buisson Les glycopeptides restent-ils le traitement de ŕf́rence des infections nosocomiales ̀ SARM:? Med. Mal. Infect. 32 2002 S184 S187
8. F. Jehl Pharmacocińtique et pharmacodynamie des glycopeptides Antibiotiques 5 2003 89 98
9. Georges B. Infections sévères à Staphylococcus aureus méticillinorésistants. Emergence de résistance à l'acide fusidique ou à la fosfomycine lors de traitement par vancomycine en perfusion continue. La Presse Médicale 5 avril 1997/26/n°11.
10. M.V. Singer, R. Haft, and T. Barlam Vancomycin control measures at tertiary-care hospital: impact of interventions on volumes and patterns of use Infect. Control. Hops Epidemiol 19 1998 248 253
11. floret N, Thalamy B, Estavoyer JM, Thouverze M, Talon D. Evaluation retrospective des prescriptions de vancomycine dans un hôpital universitaire. HYGIENES-2002-VolumeX-N°5.
12. M. Garrouste-Orgeas, J.F. Timsit, and H. Kallel Colonisation with methicillin-resistant Staphylococcus aureus in ICU patients: mordidity, mortality, an glycopeptide use Infect. Control Hosp. Epidemiol. 22 2001 687 692
13. D. Lepelletier Surveillance et contr̂le des infections ̀ Staphylococcus aureus ŕsistants ̀ la ḿticilline dans les ĥpitaux fraņais BEH 23 2001 97 99 (6 juin 2000)
14. T.L. Smith, M.L. Pearson, and K.R. Wilcox Emergence of vancomycin resistance in Staphylococcus aureus N. Engl. J. Med. 340 1999 493 501
15. F.A. Waldogel New resistance in Staphylococcus aureus N. Engl. J. Med. 340 1999 556 557
16. M.E. Martin, and K.J. Kortas Vancomycin use in a university medical center:: comparaison with Hospital infection control practices advisory committee guidelines Infect. Control Hosp. Epidemiol. 17 1996 356 359
17. M.D. Dragana, L.T. Susan, and J.M. Arthur Prospective vancomycin audit in Auckland Healthcare N. Z. Med. J. 112 1999 336 339
18. V.J. Steven, L. Lori, and V.B. Kyle Inappropriate Vancomycin prescribing based on criteria from Centers for disease control an prevention Pharmacotherapy 15 5 1995 579 585
19. W.G. Leader, M.H. Chandler, and M. Castiglia Pharmacokinetic optimisation of vancomycin therapy Clin. Pharmacokinet. 28 1995 327 342
20. G. Beaucaire Prise en charge des infections ̀ SARM par les glycopeptides: quelles limites:? Antibiotiques 6 2004 79 82 (5)
21. L. Legout Teicoplanine en ŕanimation:: taux śriques apr̀s dose de charge Juin 2001 CA 103. JNI Nante [ŕsuḿ]
22. F. Pea, L. Porreca, M. Baraldo, and M. Furlanut High. Vancomycin dosage regimens required by intensive care patients cotreated with drugs to imptrove haemodynamics following cardiac surgical procedures J. Antimicrob. Chemother. 45 3 2000 329 335
23. H. Georges Pulmonary disposition of vancomycin in critically ill patients Eur. J. Clin. Microbiol. Dis. 16 5 1997 385 388